(Q36667809)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

review article

1 reference

title

Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1

Cees G M Kallenberg

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

author name string

Coen A Stegeman

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

publication date

1 December 2006

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

Nature Clinical Practice Rheumatology

22 December 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

volume

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

page(s)

661-670

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

The American College of Rheumatology 1990 criteria for the classification of vasculitis. Introduction

22 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Nomenclature of systemic vasculitides. Proposal of an international consensus conference

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Medium- and large-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Immune complex deposits in ANCA-associated crescentic glomerulonephritis: a study of 126 cases

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Anti-neutrophil cytoplasmic antibodies: current diagnostic and pathophysiological potential

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

International Consensus Statement on Testing and Reporting of Antineutrophil Cytoplasmic Antibodies (ANCA)

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

The role of antineutrophil cytoplasmic antibody (c-ANCA) testing in the diagnosis of Wegener granulomatosis. A literature review and meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Churg-Strauss syndrome: just one disease entity?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antiproteinase 3- and antimyeloperoxidase-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Anti-neutrophil cytoplasmic antibody (ANCA) levels directed against proteinase-3 and myeloperoxidase are helpful in predicting disease relapse in ANCA-associated small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Neutrophil activation by anti-proteinase 3 antibodies in Wegener's granulomatosis: role of exogenous arachidonic acid and leukotriene B4 generation

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA): a Fc gamma RII-dependent process

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Activation of the G(i) heterotrimeric G protein by ANCA IgG F(ab')2 fragments is necessary but not sufficient to stimulate the recruitment of those downstream mediators used by intact ANCA IgG.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Membrane expression of proteinase 3 is genetically determined

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Neutrophil membrane expression of proteinase 3 (PR3) is related to relapse in PR3-ANCA-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Constitutive membrane expression of proteinase 3 (PR3) and neutrophil activation by anti-PR3 antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Expression of myeloperoxidase (MPO) by neutrophils is necessary for their activation by anti-neutrophil cytoplasm autoantibodies (ANCA) against MPO

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antineutrophil cytoplasmic antibodies induce human monocytes to produce oxygen radicals in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antineutrophil cytoplasmic antibodies induce decreased CD62L expression and enhanced metabolic activity in monocytes

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Association of chronic nasal carriage of Staphylococcus aureus and higher relapse rates in Wegener granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Trimethoprim-sulfamethoxazole (co-trimoxazole) for the prevention of relapses of Wegener's granulomatosis. Dutch Co-Trimoxazole Wegener Study Group

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Anti-proteinase-3 (PR3) antibodies (C-ANCA) recognize various targets on the human umbilical vein endothelial cell (HUVEC) membrane

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Endothelial cells and renal epithelial cells do not express the Wegener's autoantigen, proteinase 3.

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Off balance: T-cells in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antimyeloperoxidase-associated proliferative glomerulonephritis: an animal model

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antimyeloperoxidase-associated lung disease. An experimental model

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Aggravation of anti-myeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide: role of tumor necrosis factor-alpha

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

The role of neutrophils in the induction of glomerulonephritis by anti-myeloperoxidase antibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Wegener Granulomatosis: An Analysis of 158 Patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

A randomized trial of maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Maintenance therapy for vasculitis associated with antineutrophil cytoplasmic autoantibodies

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Etanercept plus standard therapy for Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Safety and efficacy of TNFalpha blockade in relapsing vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Oral antihyperglycemic agents and renal disease: new agents, new concepts

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Randomized trial of cyclophosphamide versus methotrexate for induction of remission in early systemic antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Induction of remission by B lymphocyte depletion in eleven patients with refractory antineutrophil cytoplasmic antibody-associated vasculitis

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Anti-neutrophil cytoplasmic autoantibodies and leukocyte-endothelial interactions: a sticky connection?

1 reference

https://api.crossref.org/works/10.1038%2FNCPRHEUM0355

7 January 2021

Identifiers

DOI

10.1038/NCPRHEUM0355

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17133251%20AND%20SRC:MED&resulttype=core&format=json

22 December 2019

1 reference